Markets:

Overview

News

Currencies

International

Treasuries

ARS Pharmaceuticals, Inc. - Common Stock (NQ:SPRY)

5.580 +0.030 (+0.54%)

Streaming Delayed Price Updated: 9:30 AM EDT, Aug 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ARS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Instacart, ARS Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

September 20, 2023

U.S. stock futures traded higher this morning on Wednesday. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

FDA Issues Complete Response Letter for neffy® (epinephrine nasal spray) New Drug Application with Request for Additional Study

September 19, 2023

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

ARS Reports Second Quarter 2023 Financial Results and Provides Business Updates

August 10, 2023

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

Analyst Expectations for ARS Pharmaceuticals's Future ↗

June 21, 2023

Via Benzinga

ARS Pharmaceuticals Announces PDUFA Date Extension for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis

June 20, 2023

Additional Time Needed for Labeling and Post-Marketing Requirements Discussions; PDUFA Date Set for September 19, 2023

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results

May 15, 2023

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

ONEOK, PacWest Bancorp And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

May 15, 2023

U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Nasdaq Down 100 Points; Crude Oil Drops Over 1% ↗

May 12, 2023

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 100 points on Friday. The Dow traded down 0.43% to 33,164.71 while the NASDAQ fell 0.82% to 12,227.60. The...

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

May 12, 2023

Via Benzinga

FDA Issues Some Concerns Regarding ARS Pharma's Investigational Allergy Treatment ↗

May 09, 2023

The FDA released

Via Benzinga

Why Heron Therapeutics Shares Are Trading Lower By 34%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

May 12, 2023

Gainers GSI Technology, Inc. (NASDAQ: GSIT) shares surged 108% to $3.4207. GSI Technology is expected to announce financial results for its fiscal fourth quarter after the market close on May 16,...

Via Benzinga

Dow Turns Lower; Getaround Shares Jump ↗

May 12, 2023

U.S. stocks traded lower midway through trading, with the Dow Jones turning lower on Friday. The Dow traded down 0.25% to 33,226.13 while the NASDAQ fell 0.45% to 12,271.22. The S&P 500, also fell,...

Via Benzinga

Arlo Technologies, Array Technologies, AirSculpt Technologies And Other Big Stocks Moving Higher On Friday ↗

May 12, 2023

U.S. stocks traded slightly lower, with the Dow Jones dropping around 15 points on Friday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Why ARS Pharmaceuticals Stock Is Soaring Today ↗

May 12, 2023

The FDA's Pulmonary-Allergy Drug Advisory Committee voted 16-6 in favor of ARS Pharmaceuticals Inc's (NASDAQ: SPRY) neffy in treating severe allergic reactions for adults (and 16-5 for

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

May 12, 2023

Via Benzinga

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

May 12, 2023

From The Schall Law Firm

Via Business Wire

FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis

May 11, 2023

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

May 10, 2023

From The Schall Law Firm

Via Business Wire

Why MBIA Shares Are Trading Lower By 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

May 10, 2023

Gainers Unique Fabricating, Inc. (NYSE: UFAB) climbed 205% to $0.55 after gaining around 4% on Tuesday.

Via Benzinga

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of ARS Pharmaceuticals, Inc. (SPRY) Investigation

May 10, 2023

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

ARS Pharmaceuticals Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on neffy® for the Treatment of Type I Allergic Reactions Including Anaphylaxis

May 09, 2023

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

ARS Pharmaceuticals Announces FDA Advisory Committee for neffy® for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis

March 28, 2023

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

Why Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

March 27, 2023

Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 59.6% to $0.2513. Crown Electrokinetics said it has entered into an agreement with a leading infrastructure solutions provider.

Via Benzinga

BioNTech, Coinbase Global, Pharming Group And Other Big Stocks Moving Lower On Monday ↗

March 27, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

ARS Pharmaceuticals Highlights Progress and Reports Fourth Quarter and Full Year 2022 Financial Results

March 23, 2023

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors

February 23, 2023

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis

February 22, 2023

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023

February 09, 2023

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023 ↗

January 31, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 4, 2023 ↗

January 04, 2023

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Oil & Gas Journal starts where other industry publications stop. It delivers more than information; it delivers context, adding details the others leave out and combining them with analysis, commentary, industry trends, and statistics.

Newsletters

The top stories, industry insights and relevant research, assembled by our editors and delivered to your inbox.

Connect

http://www.facebook.com/ogjonline

https://www.linkedin.com/company/oil-&-gas-journal

http://twitter.com/ogjonline

Affiliated Brands

About Us
Advertise
Do Not Sell or Share
Privacy Policy
Terms & Conditions